Gambaran Umum
Riset Klinikal
Info Kontak
Gambaran Umum
Pusat Penelitian Klinis Mahkota (CRC) didirikan untuk melakukan uji klinis berkualitas dan etis dalam upaya kami untuk berperan dalam kemajuan perawatan medis. Kami telah melakukan berbagai uji klinis berbagai disiplin ilmu termasuk kanker, hipertensi dan diabetes.
Uji klinis dilakukan oleh dokter yang bersertifikat Good Clinical Practice (GCP). Bersama dengan tim apoteker, ilmuwan laboratorium, dan perawat kami, pasien dengan hati-hati dipantau melalui uji coba yang dilakukan.
Praktik Klinik yang Baik didefinisikan sebagai
“Standar untuk desain, pelaksanaan, kinerja, pemantauan, audit, pencatatan, analisis, dan pelaporan uji klinis yang memberikan jaminan bahwa data dan hasil yang dilaporkan kredibel dan akurat, dan bahwa hak, integritas, dan kerahasiaan subjek uji coba dilindungi. ”
SHOULD I VOLUNTEER?
HARUSKAH SAYA MENJADI SUKARELAWAN?
我应该成为志愿受试者吗?
Riset Klinikal
Pusat Penelitian Klinis dengan bangga mengumumkan uji klinis aktif yang sedang berlangsung seperti di bawah ini:
| No. | Protocol ID | Judul Studi | Penyelidik |
|---|---|---|---|
| 1. | Samson-II | A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer Download to learn more |
Dr Sanjeev Chopra / Dr Hayani Abd. Wahid |
Jika anda memerlukan informasi lebih lanjut, silahkan hubungi Penyelidik Utama atau Ms Loo Siew Mei di +606-285 2946 / loo.sm@mahkotamedical.com
Uji coba masih dilakukan tetapi telah menghentikan perekrutan:
| No. | Protocol ID | Judul Studi | Penyelidik |
|---|---|---|---|
| 1. | Z100-01 | Randomized, Double-Blind, Placebo-Controlled Trial of Z-100 Plus Radiation Therapy in Patients With Local Advanced Cervical Cancer – A Phase III Trial | Dr Sanjeev Chandra Joshi |
| 2. | ARISE | A multi-center prospective non-interventional study investigating the clinical effectiveness of Ryzodeg® (Insulin Degludec/Insulin Aspart) in patients with type 2 diabetes mellitus in a real world setting | Dr Lim Siang Chin / Dr Yew Shiong Shiong |
Uji coba yang telah selesai dan ditutup:
| No. | Protocol ID | Judul Studi | Penyelidik |
|---|---|---|---|
| 1. | IHN01 | Phase III double-blind, placebo-controlled study of post-operative adjuvant concurrent chemoradiotherapy (CTRT) with or without Nimotuzumab for Stage III/IV head and neck squamous cell cancer | Dr Sanjeev Chandra Joshi |
| 2. | EXCELLENCE | An Observational Study on Prevalent AntiHypertensive Prescription Practices in Private Hospitals in Malaysia | Dr Ashok Philip / Dr Yew Shiong Shiong |
| 3. | GP13-301 | A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera® plus cyclophosphamide, vincristine, prednisone, followed by GP2013 or MabThera® maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma | Dr Kok Keng Weng |
| 4. | BV-NSCLC-002 | A Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, late stage (IIIb/IV) biomarker positive Non Small Cell Lung Carcinoma (NSCLC) patients eligible to receive standard treatment and supportive care | Dr Sanjeev Chandra Joshi |
| 5. | B7391003 | A Phase 3 Randomized, Double-Blind Study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Pacitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer | Dr Sanjeev Chandra Joshi |
| 6. | IMCL CP12-0919 | A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH) | Dr Jayendran Dharmaratnam |
| 7. | LA-EP06-302 | Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta® | Dr Jayendran Dharmaratnam |
